文献速递慢性肾脏病

CKD成人潜在不适当用药风险:CRIC研究

Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
PubMed 文献 · Am J Kidney Dis · 2021-05-23

基于CRIC队列3929例CKD成人,评估按2015年AGS Beers标准定义的潜在不适当用药(PIM)与CKD进展、住院、死亡及跌倒的关联。校正后PIM数量与住院率和死亡率呈分级关联,≥3种PIM与跌倒风险升高相关,但PIM与CKD进展或肾脏替代治疗无关。

要点

  • PIM数量与住院率和死亡率呈分级关联,≥3种PIM风险最高
  • ≥3种PIM与跌倒风险升高相关(校正OR 2.85)
  • PIM与CKD进展或肾脏替代治疗无显著关联

核心结论

  • CKD成人使用PIM与住院、死亡和跌倒风险升高相关,且风险随PIM数量增加而增大。
  • PIM与CKD进展或肾脏替代治疗启动无显著关联。

研究设计与样本

  • PIM定义为2015年美国老年医学会Beers标准中老年人应避免使用的任何药物处方。

主要发现

  • 最常处方的PIM为质子泵抑制剂和α受体阻滞剂。
  • 校正后使用1、2、≥3种PIM的住院率比分别为1.09(95%CI 1.01-1.17)、1.18(95%CI 1.07-1.30)、1.35(95%CI 1.19-1.53)。
  • 校正后使用1、2、≥3种PIM的死亡OR分别为1.19(95%CI 0.91-1.54)、1.62(95%CI 1.21-2.17)、1.65(95%CI 1.14-2.41)。
  • 跌倒亚组(n=1,109)中≥3种PIM与跌倒风险升高相关(校正OR 2.85,95%CI 1.54-5.26)。
  • PIM与CKD进展或肾脏替代治疗无显著关联,年龄未修饰PIM数量与结局的关联。

关键数值与推荐

  • PIM定义依据2015年AGS Beers标准。
  • 校正后≥3种PIM住院率比1.35(95%CI 1.19-1.53)、死亡OR 1.65(95%CI 1.14-2.41)。
  • 跌倒亚组≥3种PIM校正OR 2.85(95%CI 1.54-5.26)。

临床怎么用

  • 对CKD成人应审查Beers标准所列PIM,尤其是质子泵抑制剂和α受体阻滞剂。
  • PIM数量越多住院、死亡和跌倒风险越高,应优先减少多重PIM暴露。

局限性

  • 存在测量偏倚。
  • 存在适应证混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Adults with chronic kidney disease (CKD) may be at increased risk of adverse effects from use of potentially inappropriate medications (PIMs). Our objective was to assess whether PIM exposure has an independent association with CKD progression, hospitalizations, mortality, or falls. STUDY DESIGN: Retrospective observational study. SETTING & PARTICIPANTS: Chronic Renal Insufficiency Cohort (CRIC) study; 3,929 adults with CKD enrolled 2003-2008 and followed prospectively until December 2011. EXPOSURE: PIM exposure was defined as prescriptions for any medications to be avoided in older adults as defined by the 2015 American Geriatrics Society Beers Criteria. OUTCOME: Hospitalization count, death, a composite kidney disease end point of CKD progression or initiation of kidney replacement therapy (KRT), KRT, and fall events assessed 1 year after PIM exposure. ANALYTICAL APPROACH: Logistic regression and Poisson regression to estimate the associations of PIM exposure with each outcome. RESULTS: The most commonly prescribed PIMs were proton pump inhibitors and α-blockers. In unadjusted models, any PIM exposure (compared to none) was associated with hospitalizations, death, and fall events. After adjustment, exposure to 1, 2, or≥3 PIMs had a graded association with a higher hospitalization rate (rate ratios of 1.09 [95% CI, 1.01-1.17], 1.18 [95% CI, 1.07-1.30], and 1.35 [95% CI, 1.19-1.53], respectively) and higher odds of mortality (odds ratios of 1.19 [95% CI, 0.91-1.54], 1.62 [95% CI, 1.21-2.17], and 1.65 [95% CI, 1.14-2.41], respectively). In a cohort subset reporting falls (n=1,109), prescriptions for≥3 PIMs were associated with an increased risk of falls (adjusted OR, 2.85 [95% CI, 1.54-5.26]). PIMs were not associated with CKD progression or KRT. Age did not modify the association between PIM count and outcomes. LIMITATIONS: Measurement bias; confounding by indication. CONCLUSIONS: Adults of any age with CKD who are prescribed PIMs have an increased risk of hospitalization, mortality, and falls with the greatest risk occurring after more than 1 PIM prescription.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Hall RK, Blumenthal JB, Doerfler RM, et al. Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021. PMID: 34029681. doi:10.1053/j.ajkd.2021.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。